# Dare Bioscience (DARE) — News DARE · NASDAQ · Stock Canonical page: https://www.lighthorse.io/tickers/dare/news ## Recent headlines - [Jardine Matheson sees 2026 underlying EPS $5.50-$5.65](https://www.ainvest.com/news/jardine-matheson-sees-2026-underlying-eps-5-50-5-65-2610) — AInvest Wire, Oct 13, 2026 Jardine Matheson Holdings Limited (JARD) has reaffirmed its full-year 2026 earnings guidance, with underlying earnings per share (EPS) expected to range between $5.50 and $5.65. This projection aligns with the company’s performance in the first quarter of 2026, which delivered results marginally… - [Dare Bioscience - Notified by Nasdaq of non-compliance with minimum bid price requirement - SEC filing](https://www.ainvest.com/news/bioscience-notified-nasdaq-compliance-minimum-bid-price-requirement-sec-filing-2610) — AInvest Wire, Oct 2, 2026 Daré Bioscience, Inc. (NASDAQ: DARE) has been notified by Nasdaq that it is not in compliance with the minimum bid price requirement under Nasdaq Listing Rule 5505(a)(2). The notification was disclosed in a recent SEC filing, indicating that the company’s stock has failed to maintain a minimum bid… - [Dare Bioscience announces new U.S. patent strengthening Dare-HPV program as a potential first FDA-approved pharmacologic treatment for HPV infection](https://www.ainvest.com/news/bioscience-announces-patent-strengthening-hpv-program-potential-fda-approved-pharmacologic-treatment-hpv-infection-2609) — AInvest Wire, Sep 28, 2026 Daré Bioscience, Inc. (NASDAQ: DARE) has announced the issuance of a new U.S. patent that strengthens its DARE-HPV program, a potential first FDA-approved pharmacologic treatment for persistent high-risk human papillomavirus (HPV) infection. The patent, which covers the proprietary formulation and… - [Dare Bioscience - Files for resale of up to 8,934,345 shares of common stock - SEC filing](https://www.ainvest.com/news/bioscience-files-resale-8-934-345-shares-common-stock-sec-filing-2608) — AInvest Wire, Aug 26, 2026 Daré Bioscience, Inc. (NASDAQ: DARE) has filed with the U.S. Securities and Exchange Commission (SEC) to resell up to 8,934,345 shares of its common stock, according to recent SEC filings. The filing, dated August 24, 2026, is in the form of Schedule 13G, which typically discloses significant… - [Daré Bioscience announces pricing of $6.0 million registered direct offering priced at-the-market under Nasdaq rules](https://www.ainvest.com/news/dar-bioscience-announces-pricing-6-0-million-registered-direct-offering-priced-market-nasdaq-rules-2608) — AInvest Wire, Aug 14, 2026 Daré Bioscience, Inc. (NASDAQ: DARE) has announced the pricing of a $6.0 million registered direct offering under Nasdaq rules. The offering includes the sale of 10,000,000 shares of the company’s common stock and warrants to purchase up to 10,000,000 shares of common stock. Each warrant is… --- Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express. This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness. Data provided by [AInvest](https://www.ainvest.com).